TRACON Pharmaceuticals (TCON)
(Delayed Data from NSDQ)
$1.45 USD
-0.04 (-2.68%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $1.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Brokerage Reports
TRACON Pharmaceuticals, Inc. [TCON]
Reports for Purchase
Showing records 1 - 20 ( 70 total )
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
IDMC Recommends ENVASARC Phase 2 Pivotal Trial to Continue; Lower ORR by BICR Observed; Lowering PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Pivotal ENVASARC Trial Expected to Complete Enrollment This Month; Lowering PT by $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Product Development Platform Deal Yields $3M Upfront Payment
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; More Interim Data From ENVASARC Pivotal Phase 2 Trial Expected by YE23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; ENVASARC Trial''s Second and Final Interim Analysis Expected in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Arbitration Outcome Lengthens Cash Runway Guidance
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Next Interim Analysis From ENVASARC Study in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Up to $30 Million Non-Recourse Financing Agreement Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive IDMC Interim Efficacy Review From the ENVASARC Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in Phase 1/2 Trial of YH001 in Combination With Envafolimab and Doxorubicin in Front Line Sarcoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; ENVASARC IDMC Efficacy Review Expected Later This Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
IDMC Review of 12 Week Safety Data From ENVASARC Study Results in Recommendation to Proceed as Planned
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ICC Extends Time Limit For Decision in I-Mab Arbitration
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Envafolimab Receives Fast Track Designation From FDA for UPS and MFS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves IND for Phase 1/2 Trial of YH001 in Combination With Envafolimab and Doxorubicin in Sarcoma Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; First Interim Efficacy Data From Pivotal Envafolimab Trial Expected 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: TRACON Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal ENVASARC Trial Doses 36th Patient, Triggering Initial IDMC Efficacy Review to Proceed
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department